Taysha Gene Therapies Inc

For the period ended Jun 30, 2024. Filed Aug 12, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 12, 2024

TSHA$4.28-2.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Statements of Stockholders’ (Deficit) Equity

Condensed Consolidated Statements of Stockholders’ (Deficit) Equity

(in thousands, except share data)

For the Three Months Ended June 30, 2024

Additional · Accumulated · Total
Common Stock · Paid-in · Accumulated · Other · Stockholders'
	Shares	Amount	Capital	Deficit	Comprehensive Loss	Deficit
Balance as of March 31, 2024	187,018,275	$2	$591,166	$(537,068)	$(251)	$53,849
Stock-based compensation	—	—	3,332	—	—	3,332
Issuance of common stock and pre-funded warrants upon closing of underwritten public offering, net of underwriting discounts and commissions, and other offering costs of $5,024	14,361,113	—	69,957	—	—	69,957
Issuance of common stock upon exercise of stock options, net	2,062	—	2	—	—	2
Loss on instrument-specific credit risk	—	—	—	—	2,656	2,656
Net loss	—	—	—	(20,928)	—	(20,928)
Balance as of June 30, 2024	201,381,450	$2	$664,457	$(557,996)	$2,405	$108,868

For the Three Months Ended June 30, 2023

Additional · Accumulated · Total
Common Stock · Paid-in · Accumulated · Other · Stockholders'
	Shares	Amount	Capital	Deficit	Comprehensive Loss	Equity
Balance as of March 31, 2023	63,473,349	$1	$404,114	$(419,063)	$—	$(14,948)
Stock-based compensation	—	—	2,222	—	—	2,222
Issuance of common stock in private placement, net of offering costs of $40	705,218	—	210	—	—	210
Issuance of common stock upon vesting and settlement of restricted stock units	254,070	—	—	—	—	—
Net loss	—	—	—	(24,598)	—	(24,598)
Balance as of June 30, 2023	64,432,637	$1	$406,546	$(443,661)	$—	$(37,114)

Condensed Consolidated Statements of Stockholders’ (Deficit) Equity

(in thousands, except share data)

For the Six Months Ended June 30, 2024

Additional
Common Stock · Paid-in · Accumulated · Accumulated Other · Total
	Shares	Amount	Capital	Deficit	Comprehensive Loss	Stockholders' Equity
Balance as of December 31, 2023	186,960,193	$2	$587,942	$(513,007)	$—	$74,937
Stock-based compensation	—	—	6,530	—	—	6,530
Issuance of common stock and pre-funded warrants upon closing of underwritten public offering, net of underwriting discounts and commissions, and other offering costs of $5,024	14,361,113	—	69,957	—	—	69,957
Issuance of common stock upon vesting and settlement of restricted stock units	11,282	—	—	—	—	—
Issuance of common stock under ESPP	46,800	—	26	—	—	26
Issuance of common stock upon exercise of stock options	2,062	—	2	—	—	2
Gain on instrument-specific credit risk	—	—	—	—	2,405	2,405
Net loss	—	—	—	(44,989)	—	(44,989)
Balance as of June 30, 2024	201,381,450	$2	$664,457	$(557,996)	$2,405	$108,868

For the Six Months Ended June 30, 2023

Additional · Total
Common Stock · Paid-in · Accumulated · Accumulated Other · Stockholders'
	Shares	Amount	Capital	Deficit	Comprehensive Loss	Equity (Deficit)
Balance as of December 31, 2022	63,207,507	$1	$402,389	$(401,441)	$—	$949
Stock-based compensation	—	—	3,897	—	—	3,897
Issuance of common stock in private placement, net of offering costs of $40	705,218	—	210	—	—	210
Issuance of common stock upon vesting and settlement of restricted stock units, net	483,992	—	—	—	—	—
Issuance of common stock under ESPP	35,920	—	50	—	—	50
Net loss	—	—	—	(42,220)	—	(42,220)
Balance as of June 30, 2023	64,432,637	$1	$406,546	$(443,661)	$—	$(37,114)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.